$BPTH
BIO-PATH HOLDINGS, INC.

2023 Q1 Form 10-K Financial Statement

#000155837023005081 Filed on March 30, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2022
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.303M $1.123M $4.736M
YoY Change 3.33% -7.11% 4.48%
% of Gross Profit
Research & Development $3.989M $2.863M $9.165M
YoY Change 90.13% -1.55% 55.08%
% of Gross Profit
Depreciation & Amortization $22.00K $23.00K $100.0K
YoY Change 0.0% 15.0% 0.0%
% of Gross Profit
Operating Expenses $5.292M $3.986M $13.90M
YoY Change 57.55% -3.18% 33.11%
Operating Profit -$5.292M -$13.90M
YoY Change 57.55% 33.11%
Interest Expense $19.00K $20.00K $33.00K
YoY Change 1900.0% 1000.0%
% of Operating Profit
Other Income/Expense, Net $19.00K $33.00K
YoY Change 1000.0%
Pretax Income -$5.273M -$3.966M -$13.87M
YoY Change 56.98% -3.64% 32.84%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$5.273M -$3.966M -$13.90M
YoY Change 56.98% -3.64% 33.65%
Net Earnings / Revenue
Basic Earnings Per Share -$0.66 -$1.91
Diluted Earnings Per Share -$0.66 -$0.52 -$1.91
COMMON SHARES
Basic Shares Outstanding 7.960M 7.960M 7.276M
Diluted Shares Outstanding 7.960M 7.276M

Balance Sheet

Concept 2023 Q1 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $6.731M $10.38M $10.38M
YoY Change -68.32% -56.32% -56.32%
Cash & Equivalents $6.731M $10.38M
Short-Term Investments
Other Short-Term Assets $1.664M $1.644M $5.231M
YoY Change 18.01% -10.8% 121.09%
Inventory
Prepaid Expenses $2.396M $3.587M
Receivables
Other Receivables
Total Short-Term Assets $10.79M $15.62M $15.62M
YoY Change -54.29% -40.26% -40.26%
LONG-TERM ASSETS
Property, Plant & Equipment $136.0K $158.0K $356.0K
YoY Change -33.0% -29.78% -16.82%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $311.0K $356.0K $356.0K
YoY Change -33.55% -16.82% -16.82%
TOTAL ASSETS
Total Short-Term Assets $10.79M $15.62M $15.62M
Total Long-Term Assets $311.0K $356.0K $356.0K
Total Assets $11.10M $15.97M $15.97M
YoY Change -53.89% -39.89% -39.89%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $827.0K $667.0K -$33.00K
YoY Change 106.75% 567.0% -650.0%
Accrued Expenses $973.0K $900.0K $1.017M
YoY Change -11.55% 12.5% 19.37%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.910M $1.684M $1.684M
YoY Change 21.81% 75.78% 75.78%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $85.00K $113.0K $113.0K
YoY Change -56.41% -26.14% -26.14%
Total Long-Term Liabilities $85.00K $113.0K $113.0K
YoY Change -56.41% -26.14% -26.14%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.910M $1.684M $1.684M
Total Long-Term Liabilities $85.00K $113.0K $113.0K
Total Liabilities $1.995M $1.797M $1.797M
YoY Change 13.16% 61.75% 61.75%
SHAREHOLDERS EQUITY
Retained Earnings -$96.80M -$91.50M
YoY Change 19.48% 17.82%
Common Stock $8.000K $8.000K
YoY Change 14.29% 14.29%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $9.107M $14.17M $14.17M
YoY Change
Total Liabilities & Shareholders Equity $11.10M $15.97M $15.97M
YoY Change -53.89% -39.89% -39.89%

Cashflow Statement

Concept 2023 Q1 2022 Q4 2022
OPERATING ACTIVITIES
Net Income -$5.273M -$3.966M -$13.90M
YoY Change 56.98% -3.64% 33.65%
Depreciation, Depletion And Amortization $22.00K $23.00K $100.0K
YoY Change 0.0% 15.0% 0.0%
Cash From Operating Activities -$3.653M -$5.000M -$15.10M
YoY Change 44.62% 78.51% 52.29%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $21.00K
YoY Change -100.0% -70.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 -$21.00K
YoY Change -100.0% -70.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $1.734M
YoY Change -89.06%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.734M 1.734M
YoY Change -57900.0% -91.33%
NET CHANGE
Cash From Operating Activities -3.653M -5.000M -15.10M
Cash From Investing Activities 0.000 -21.00K
Cash From Financing Activities 1.734M 1.734M
Net Change In Cash -3.653M -3.266M -13.39M
YoY Change 44.62% 15.53% -233.65%
FREE CASH FLOW
Cash From Operating Activities -$3.653M -$5.000M -$15.10M
Capital Expenditures $0.00 $21.00K
Free Cash Flow -$5.000M -$15.12M
YoY Change 79.99% 51.44%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7276000
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6725000
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001133818
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7160000
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7960000
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.91
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.55
CY2022 bpth Term Commitments Are Incurred
TermCommitmentsAreIncurred
P12M
CY2019Q2 us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2022 us-gaap Operating Loss Carryforwards Expiration Date
OperatingLossCarryforwardsExpirationDate
2037-12-31
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
001-36333
CY2022 dei Entity Registrant Name
EntityRegistrantName
BIO-PATH HOLDINGS, INC.
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
87-0652870
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
4710 Bellaire Boulevard, Suite 210
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Bellaire
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
77401
CY2022 dei City Area Code
CityAreaCode
832
CY2022 dei Local Phone Number
LocalPhoneNumber
742-1357
CY2022 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2022 dei Trading Symbol
TradingSymbol
BPTH
CY2022 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
7960164
CY2022Q2 dei Entity Public Float
EntityPublicFloat
27578277.90
CY2022 dei Auditor Firm
AuditorFirmId
42
CY2022 dei Auditor Name
AuditorName
Ernst & Young LLP
CY2022 dei Auditor Location
AuditorLocation
Houston, Texas
CY2022Q4 us-gaap Cash
Cash
10384000
CY2021Q4 us-gaap Cash
Cash
23774000
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
3587000
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
523000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1644000
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1843000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
15615000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
26140000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1120000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1099000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
962000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
874000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
158000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
225000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
198000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
203000
CY2022Q4 us-gaap Assets
Assets
15971000
CY2021Q4 us-gaap Assets
Assets
26568000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
667000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
106000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
909000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
770000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
108000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
82000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1684000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
958000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
113000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
153000
CY2022Q4 us-gaap Liabilities
Liabilities
1797000
CY2021Q4 us-gaap Liabilities
Liabilities
1111000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7960000
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7160000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
8000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
7000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
105695000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
103111000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-91529000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-77661000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
14174000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
25457000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
15971000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
26568000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9165000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5910000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4736000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4533000
CY2022 us-gaap Operating Expenses
OperatingExpenses
13901000
CY2021 us-gaap Operating Expenses
OperatingExpenses
10443000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-13901000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-10443000
CY2022 us-gaap Investment Income Interest
InvestmentIncomeInterest
33000
CY2021 us-gaap Investment Income Interest
InvestmentIncomeInterest
3000
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
33000
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-13868000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-10440000
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.91
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.55
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7276000
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6725000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-13868000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-10440000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
851000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
821000
CY2022 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
90000
CY2021 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
85000
CY2022 us-gaap Depreciation
Depreciation
88000
CY2021 us-gaap Depreciation
Depreciation
76000
CY2022 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
3064000
CY2021 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-750000
CY2022 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-199000
CY2021 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
915000
CY2022 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
700000
CY2021 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-199000
CY2022 bpth Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
99000
CY2021 bpth Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
95000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15103000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9917000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
21000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
70000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-21000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-70000
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1734000
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
15849000
CY2021 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
4157000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1734000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
20006000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-13390000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
10019000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
23774000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13755000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10384000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
23774000
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
85000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
15070000
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
15849000
CY2021 bpth Stock Issue During Period Value Warrants Exercised
StockIssueDuringPeriodValueWarrantsExercised
4157000
CY2021 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
821000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-10440000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
25457000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
25457000
CY2022 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1734000
CY2022 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
851000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-13868000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
14174000
CY2022 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Concentration of Credit Risk — </span>Financial instruments that potentially subject the Company to a significant concentration of credit risk consist of cash. The Company maintains its cash balances with one major commercial bank, JPMorgan Chase Bank. The balances are insured by the Federal Deposit Insurance Corporation (the “FDIC”) up to $250,000. As a result, as of December 31, 2022, approximately $10.1 million of its cash balance was not covered by the FDIC. As of December 31, 2021, the Company had approximately $23.8 million in cash on-hand, of which approximately $23.5 million was not covered by the FDIC. To date, the Company has not incurred any losses on its cash balances.</p>
CY2021 us-gaap Depreciation
Depreciation
100000
CY2022 us-gaap Depreciation
Depreciation
100000
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
657408
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
485908
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates —</span> The preparation of consolidated financial statements in conformity with generally accepted accounting principles in the United States (“U.S.”) requires management to make estimates and assumptions that affect the amounts reported in the Company’s consolidated financial statements and accompanying notes. On an ongoing basis, the Company evaluates its estimates and judgments, which are based on historical and anticipated results and trends as well as on various other assumptions that the Company believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from the Company’s estimates. These estimates include accrued clinical trial costs, stock-based compensation expense, valuation of warrants and valuation of deferred tax assets.</p>
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-13900000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-10400000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-91500000
CY2022Q4 us-gaap Cash
Cash
10400000
CY2022Q4 us-gaap Debt Longterm And Shortterm Combined Amount
DebtLongtermAndShorttermCombinedAmount
0
CY2021Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
500000
CY2022Q4 bpth Expected Advanced Payment To Be Expensed
ExpectedAdvancedPaymentToBeExpensed
3600000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1120000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1099000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
962000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
874000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
158000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
225000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
900000
CY2022Q4 bpth Accrued Vacation And Bonus
AccruedVacationAndBonus
400000
CY2022Q4 bpth Accrued Manufacturing And Testing Expenses
AccruedManufacturingAndTestingExpenses
200000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
100000
CY2022Q4 bpth Accrued Legal And Patent Fees
AccruedLegalAndPatentFees
100000
CY2022Q4 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
100000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
800000
CY2021Q4 bpth Accrued Vacation And Bonus
AccruedVacationAndBonus
400000
CY2021Q4 bpth Accrued Franchise Tax Expense
AccruedFranchiseTaxExpense
100000
CY2021Q4 bpth Accrued Legal And Patent Fees
AccruedLegalAndPatentFees
100000
CY2021Q4 bpth Accrued Manufacturing Expense
AccruedManufacturingExpense
100000
CY2021Q4 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
100000
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
12200000
CY2021 bpth Stock Issued During Period Shares Warrants Exercised
StockIssuedDuringPeriodSharesWarrantsExercised
428907
CY2021 bpth Weighted Average Exercise Price
WeightedAverageExercisePrice
9.71
CY2021 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
4200000
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.71
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.22
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0243
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0115
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.27
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.28
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
486000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
14.58
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y4M24D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
7800000
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
192000
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.71
CY2022 bpth Share Based Compensation Arrangement By Share Based Payment Award Options Granted In Period Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodContractualTerm
P9Y3M18D
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
2000
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
7.02
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
18000
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
5.96
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
658000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
11.67
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y10M24D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
634000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
11.90
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y10M24D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
321000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
18.62
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y3M18D
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
274000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
20.57
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y8M12D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
3750000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
213000
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
7.02
CY2021 bpth Share Based Compensation Arrangement By Share Based Payment Award Options Granted In Period Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodContractualTerm
P9Y3M18D
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
1000
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
72.67
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
486000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
14.58
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y4M24D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
7800000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
451000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
15.21
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y4M24D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
7114000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
178000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
28.09
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y7M6D
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
3412000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
900000
CY2022Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
1300000
CY2022 bpth Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding And Unvested Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndUnvestedWeightedAverageRemainingContractualTerm
P2Y2M12D
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
800000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
221000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
235000
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
19000000.0
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1201000
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
P4Y1M6D
CY2022 bpth Sharebased Compensation Arrangement By Sharebased Payment Award Other Than Option Outstanding Weighted Average Exercise Price Per Share
SharebasedCompensationArrangementBySharebasedPaymentAwardOtherThanOptionOutstandingWeightedAverageExercisePricePerShare
7.03
CY2022Q4 bpth Sharebased Compensation Arrangement By Sharebased Payment Award Other Than Options Exercisable Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOtherThanOptionsExercisableNumberOfShares
401000
CY2022 bpth Sharebased Compensation Arrangement By Sharebased Payment Award Other Than Options Exercisable Weighted Average Exercise Price Per Share
SharebasedCompensationArrangementBySharebasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePricePerShare
15.39
CY2022Q4 us-gaap Other Commitment Due In Next Twelve Months
OtherCommitmentDueInNextTwelveMonths
2200000
CY2014Q2 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P5Y
CY2019Q2 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2016Q2 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P3Y
CY2018Q4 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P3Y
CY2022 bpth Operating Lease Incremental Borrowing Rate Utilized
OperatingLeaseIncrementalBorrowingRateUtilized
0.080
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
198000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
203000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
108000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
82000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
113000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
153000
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
115000
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
117000
CY2022 us-gaap Variable Lease Cost
VariableLeaseCost
5000
CY2021 us-gaap Variable Lease Cost
VariableLeaseCost
11000
CY2022 us-gaap Lease Cost
LeaseCost
120000
CY2021 us-gaap Lease Cost
LeaseCost
128000
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
100000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
121000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
108000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
11000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
240000
CY2022Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
19000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
221000
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y
CY2022 bpth Defined Contribution Plan Employer Matching Contribution Percent Of Match First3 Of Base Salary
DefinedContributionPlanEmployerMatchingContributionPercentOfMatchFirst3OfBaseSalary
1
CY2022 bpth Defined Contribution Plan Employer Matching Contribution Percent Of Employees Gross Pay Tranche One
DefinedContributionPlanEmployerMatchingContributionPercentOfEmployeesGrossPayTrancheOne
0.03
CY2022 bpth Defined Contribution Plan Employer Matching Contribution Percent Of Match On Next2 Of Base Salary
DefinedContributionPlanEmployerMatchingContributionPercentOfMatchOnNext2OfBaseSalary
0.50
CY2022 bpth Defined Contribution Plan Employer Matching Contribution Percent Of Employees Gross Pay Tranche Two
DefinedContributionPlanEmployerMatchingContributionPercentOfEmployeesGrossPayTrancheTwo
0.02
CY2022Q4 us-gaap Defined Benefit Plan Accumulated Benefit Obligation
DefinedBenefitPlanAccumulatedBenefitObligation
37000
CY2021Q4 us-gaap Defined Benefit Plan Accumulated Benefit Obligation
DefinedBenefitPlanAccumulatedBenefitObligation
39000
CY2022Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
84300000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration
DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
36000000.0
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Not Subject To Expiration
DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration
48300000
CY2022 bpth Net Operating Loss Tax Basis
NetOperatingLossTaxBasis
75300000
CY2022 bpth Tax Credits Earned After2019
TaxCreditsEarnedAfter2019
2500000
CY2022 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
100000
CY2022 bpth Valuation Allowance As Percent Of Deferred Tax Assets
ValuationAllowanceAsPercentOfDeferredTaxAssets
1
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
19100000
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Bonuses
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses
63000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Bonuses
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses
63000
CY2022Q4 bpth Deferred Tax Asset Accrued Vacation
DeferredTaxAssetAccruedVacation
28000
CY2021Q4 bpth Deferred Tax Asset Accrued Vacation
DeferredTaxAssetAccruedVacation
26000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
15818000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
14975000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
2509000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
3353000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
671000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
572000
CY2022Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
3000
CY2021Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
4000
CY2022Q4 bpth Deferred Tax Right Of Use Liability
DeferredTaxRightOfUseLiability
-46000
CY2021Q4 bpth Deferred Tax Right Of Use Liability
DeferredTaxRightOfUseLiability
-49000
CY2022Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
44000
CY2021Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
43000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
19182000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
19085000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
19140000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
19042000
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
42000
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
43000
CY2022Q4 bpth Deferred Tax Right Of Use Asset
DeferredTaxRightOfUseAsset
-42000
CY2021Q4 bpth Deferred Tax Right Of Use Asset
DeferredTaxRightOfUseAsset
-43000
CY2022Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2021Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-13868000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10440000
CY2022 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-2912000
CY2021 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-2193000
CY2022 us-gaap Income Tax Reconciliation Deductions Extraterritorial Income Exclusion
IncomeTaxReconciliationDeductionsExtraterritorialIncomeExclusion
80000
CY2021 us-gaap Income Tax Reconciliation Deductions Extraterritorial Income Exclusion
IncomeTaxReconciliationDeductionsExtraterritorialIncomeExclusion
73000
CY2022 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
-844000
CY2021 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
451000
CY2022 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
98000
CY2021 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
2648000
CY2022 bpth Effective Income Tax Rate Reconciliation Section182 Nol Limits
EffectiveIncomeTaxRateReconciliationSection182NolLimits
1890000
CY2021 bpth Effective Income Tax Rate Reconciliation Section182 Nol Limits
EffectiveIncomeTaxRateReconciliationSection182NolLimits
0
CY2022 us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
0
CY2021 us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
-77000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2022 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2021Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2022Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0

Files In Submission

Name View Source Status
0001558370-23-005081-index-headers.html Edgar Link pending
0001558370-23-005081-index.html Edgar Link pending
0001558370-23-005081.txt Edgar Link pending
0001558370-23-005081-xbrl.zip Edgar Link pending
bpth-20221231.xsd Edgar Link pending
bpth-20221231x10k.htm Edgar Link pending
bpth-20221231x10k001.jpg Edgar Link pending
bpth-20221231x10k002.jpg Edgar Link pending
bpth-20221231x10k003.jpg Edgar Link pending
bpth-20221231x10k004.jpg Edgar Link pending
bpth-20221231xex23d1.htm Edgar Link pending
bpth-20221231xex31.htm Edgar Link pending
bpth-20221231xex32.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
bpth-20221231_cal.xml Edgar Link unprocessable
bpth-20221231_def.xml Edgar Link unprocessable
bpth-20221231_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
bpth-20221231_pre.xml Edgar Link unprocessable
bpth-20221231x10k_htm.xml Edgar Link completed
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
R9999.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending